Marisol Gomez
Optometrist · Austin, TXNPI 1285018721
Payments from drug & device makers
Across 201 payments — averaging $148.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dompe US, Inc.$18K
- Tarsus Pharmaceuticals, Inc.$4K
- Johnson & Johnson Surgical Vision, Inc.$3K
- Sun Pharmaceutical Industries Inc.$653
- Alcon Research LLC$640
- Carl Zeiss Meditec, Inc.$584
- plus $3K from 20 others
What the payments were for
- Consulting fees$2,4408%
- Speaking & faculty fees$14,28348%
- Travel & lodging$5,93920%
- Food & beverage$6,75223%
- Gifts$3731%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dompe US, Inc. | 46 | $18,117 |
| Tarsus Pharmaceuticals, Inc. | 30 | $4,080 |
| Johnson & Johnson Surgical Vision, Inc. | 19 | $2,518 |
| Sun Pharmaceutical Industries Inc. | 17 | $653 |
| Alcon Research LLC | 1 | $640 |
| Carl Zeiss Meditec, Inc. | 2 | $584 |
| Bausch & Lomb Americas Inc. | 18 | $424 |
| Shire North American Group Inc | 13 | $362 |
| Alcon | 7 | $352 |
| AbbVie | 7 | $347 |
| Rxsight Inc | 7 | $272 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $241 |
| Regeneron Healthcare Solutions, Inc. | 2 | $230 |
| Oyster Point Pharma, Inc. | 5 | $208 |
| Harrow Eye, LLC | 5 | $128 |
| Glaukos Corporation | 1 | $111 |
| Astellas Pharma US Inc | 1 | $111 |
| Kala Pharmaceuticals, Inc. | 1 | $103 |
| Biotissue Holdings Inc. | 1 | $97 |
| Thea Pharma Inc. | 3 | $53 |
| Tearlab Corp | 2 | $44 |
| Novartis | 2 | $40 |
| Amgen | 1 | $29 |
| Sight Sciences, Inc. | 1 | $15 |
| Eyepoint US, Inc. | 1 | $15 |
| Eyevance Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Oxervate$17,780
- Tecnis 1-piece IOL$1,772
- Tecnis Multifocal Family of 1-piece IOLS$1,772
- Tecnis Symfony IOL$1,772
- IOLMaster$373
- XIIDRA$242
- CIRRUS HD-OCT$211
- IOLMaster 500$211
- VisuMax$211
- CALLISTO eye$211
- ARTEVO 800$211
- Clareon$129
- LUMIGAN$124
- RXSIGHT CONTACT LENS$123
- RXSIGHT INJECTOR CARTRIDGE$123
- RXSIGHT INJECTOR HANDPIECE$123
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$123
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$123
- ARGOS$122
- EYLEA$122
How this compares
$29,786 in reported general payments places this provider in the 95th percentile of 4,315 optometrist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 57 | $85,968 |
| CequaCyclosporine | 39 | $43,160 |
| MieboPerfluorohexyloctane/Pf | 23 | $18,174 |
| VyzultaLatanoprostene Bunod | 43 | $11,398 |
| CombiganBrimonidine Tartrate/Timolol | 20 | $7,219 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 16 | $4,843 |
| ZyletTobramycin/Lotepred Etab | 14 | $4,626 |
| Lotemax SmLoteprednol Etabonate | 18 | $4,328 |
| Doxycycline Hyclate | 18 | $464 |
| Latanoprost | 34 | $458 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $424 | $115,540123 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $653 | $43,16039 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCZylet, Lotemax Sm | $241 | $8,95332 claims |
| AbbVieCombigan | $347 | $7,21920 claims |
| AlconSimbrinza | $352 | $4,84316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,315 optometrist providers in Texas.
Other optometrist in Austin
- Derek CunninghamAustin$940K
- Emile FadelAustin$225K
- Tiffany HuynhHouston$3.2M
- Bridgitte LeeHouston$3M
- Bryan FrazierTyler$1.4M
- Wendy ChungKaty$900K
- Phillip BrunsonHouston$766K
- Claudio LagunasHouston$644K
- Ashley Wallace-TuckerHouston$568K
- Mina VanrachackSan Antonio$553K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.